Vsee Health (NASDAQ:VSEE – Get Free Report) and Better Therapeutics (NASDAQ:BTTX – Get Free Report) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.
Profitability
This table compares Vsee Health and Better Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Vsee Health | N/A | -182.59% | -58.26% |
Better Therapeutics | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent recommendations and price targets for Vsee Health and Better Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vsee Health | 0 | 0 | 0 | 1 | 4.00 |
Better Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Institutional & Insider Ownership
1.0% of Vsee Health shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 6.6% of Vsee Health shares are owned by insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Vsee Health and Better Therapeutics”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vsee Health | $6.38 million | 0.73 | -$4.41 million | N/A | N/A |
Better Therapeutics | N/A | N/A | -$39.76 million | N/A | N/A |
Vsee Health has higher revenue and earnings than Better Therapeutics.
Summary
Vsee Health beats Better Therapeutics on 5 of the 9 factors compared between the two stocks.
About Vsee Health
VSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL.
About Better Therapeutics
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Vsee Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vsee Health and related companies with MarketBeat.com's FREE daily email newsletter.